Latest revenue
$362.3M
as of 2026-03-31
Latest net income
$22.3M
as of 2026-03-31
Net margin
6.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Electromedical & Electrotherapeutic Apparatus (37 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think LIVN is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.97B
- Enterprise value
- $3.72B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.28×
- Dividend yield
- 0.0%
- 52-wk high
- $75.81
- 52-wk low
- $41.02
- Beta
- —
- Shares out
- 54.9M
5-year trend
What this company does
ITEM 1. BUSINESS Description of the Business and Background LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.” Business Overview LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to…
AI summary unavailable — showing raw filing excerpt
Generated from LIVN's filing dated 2026-02-25
Key risks
ITEM 1A. RISK FACTORS An investor should carefully consider the risks described below, as well as other information contained in this Report and in LivaNova’s other filings with the SEC. The Company’s business, results of operations, cash flows, and financial condition could be materially and adversely affected by any such risks or uncertainties. Additional risks and uncertainties not presently known to the Company or that the Company currently believes to be immaterial may also adversely affect its business. Risks Relating to the Company’s Business and Operations LivaNova is subject to the risks of conducting business globally. LivaNova is subject to risks that are inherent in conducting…
AI summary unavailable — showing raw filing excerpt
Generated from LIVN's filing dated 2026-02-25
Profitability
Gross margin
67.7%
2.5%Operating margin
14.4%
39.5%Net margin
-17.5%
446.3%Return on equity
-20.2%
521.9%Return on assets
-9.3%
468.8%Leverage
Debt / equity
1.17×
30.4%Long-term debt / equity
0.29×
30.9%Debt / assets
54.0%
14.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $362.3M | +14.3% | $22.3M | +106.8% | 6.2% |
Q4 2025 2025-12-31 | $360.9M | +12.1% | $30.9M | -62.1% | 8.6% |
Q3 2025 2025-09-30 | $357.8M | +12.5% | $26.8M | +264.8% | 7.5% |
Q2 2025 2025-06-30 | $352.5M | +10.7% | $27.2M | +66.3% | 7.7% |
Q1 2025 2025-03-31 | $316.9M | +7.4% | $-327.3M | -680.4% | -103.3% |
Q4 2024 2024-12-31 | $321.8M | — | $81.5M | — | 25.3% |
Q3 2024 2024-09-30 | $318.1M | +11.2% | $7.3M | +508.4% | 2.3% |
Q2 2024 2024-06-30 | $318.6M | +8.4% | $16.3M | +1314.1% | 5.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on LIVN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$234.6K
Net activity
−$234.6K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns LIVN
Institutional value
$1.77B
Total shares held
29.0M
Distinct holders
181
-92 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.1M | $453.7M | -184.6K (-2.5%) | Trimmed |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 4.2M | $267.4M | -17.8K (-0.4%) | Trimmed |
| 3 | Artisan Partners Limited Partnership | 2.1M | $134.9M | -192.5K (-8.3%) | Trimmed |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.8M | $116.1M | +38.3K (+2.1%) | Added |
| 5 | Invesco Ltd. | 1.6M | $103.2M | +533.1K (+48.9%) | Added |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $85.4M | — | New |
| 7 | CONGRESS ASSET MANAGEMENT CO | 1.3M | $81.0M | — | New |
| 8 | Nuveen, LLC | 920.3K | $58.5M | -1.3K (-0.1%) | Trimmed |
| 9 | EMERALD ADVISERS, LLC | 670.2K | $42.6M | -30.7K (-4.4%) | Trimmed |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 648.2K | $41.2M | — | New |
| 11 | EMERALD MUTUAL FUND ADVISERS TRUST | 454.3K | $28.9M | -1.9K (-0.4%) | Trimmed |
| 12 | JPMORGAN CHASE & CO | 464.1K | $28.4M | +74.4K (+19.1%) | Added |
| 13 | Walleye Capital LLC | 427.2K | $27.2M | -222.5K (-34.3%) | Trimmed |
| 14 | Bank of New York Mellon Corp | 394.4K | $25.1M | -6.0K (-1.5%) | Trimmed |
| 15 | UBS Group AG | 370.1K | $23.5M | -177.5K (-32.4%) | Trimmed |
| 16 | KENNEDY CAPITAL MANAGEMENT LLC | 364.4K | $23.2M | +118.7K (+48.3%) | Added |
| 17 | VANGUARD FIDUCIARY TRUST CO | 309.4K | $19.7M | — | New |
| 18 | WELLS FARGO & COMPANY/MN | 256.5K | $16.3M | -110.8K (-30.2%) | Trimmed |
| 19 | SEI INVESTMENTS CO | 218.8K | $13.9M | +79.1K (+56.6%) | Added |
| 20 | Allspring Global Investments Holdings, LLC | 182.4K | $11.8M | -19.4K (-9.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once LIVN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.